Drug Profile
Research programme: androgen receptor antagonists - Praecis
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Praecis Pharmaceuticals
- Class
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 16 Feb 2007 Praecis Pharmaceuticals has been acquired by GlaxoSmithKline
- 03 Jul 2002 Preclinical trials in Prostate cancer in USA (unspecified route)